<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526705</url>
  </required_header>
  <id_info>
    <org_study_id>Kapu1</org_study_id>
    <nct_id>NCT03526705</nct_id>
  </id_info>
  <brief_title>The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis</brief_title>
  <official_title>The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis Lesional Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Psoriasis is an immune-mediated skin disease that affects 1-2 % of the population. Several
      cytokines have been found to be involved in the complex pathogenesis of this disease. Il- 36
      is one of the cytokines sharing in psoriasis pathogenesis, as its levels are elevated in
      psoriatic plaques. Cathepsin G is known to activate Il- 36 and promote inflammation in
      psoriasis.NB-UVB is one of the important treatment modalities for psoriasis.

      The aim of this study is to detect the effect of NB-UVB on the lesional levels of IL-36 in
      psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      25 psoriasis patients will receive 26 sessions of phototherapy (NB-UVB). Patients will
      receive 3 sessions per week. Tissue levels of IL-36 and Cathepsin G will be assessed in skin
      lesions before starting treatment and after completing the 26 sessions.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in Il-36 levels in 25 psoriasis patients after 26 sessions of NB-UVB</measure>
    <time_frame>6 months</time_frame>
    <description>primary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in cathepsin G levels in 25 psoriasis patients after 26 sessions of NB-UVB psoriasis</measure>
    <time_frame>6 months</time_frame>
    <description>secondary</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>nb-uvb</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>psoriasis patients will receive 26 sessions of nb-uvb phototherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NB-UVB</intervention_name>
    <description>Phototherapy</description>
    <arm_group_label>nb-uvb</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with psoriasis vulgaris of both sexes

          -  Age between 18 and 60 years old.

        Exclusion Criteria:

          -  Pregnant females

          -  Patients receiving systemic treatment or topical treatment for psoriasis within the
             past two months.

          -  Patients having other dermatological diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>July 20, 2019</last_update_submitted>
  <last_update_submitted_qc>July 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Dina Saadi</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

